Considering the tumor antigen-dependence of ADC internalization into myeloid cells, we surmised that the tumor cell-directed STINGa ADCs would activate the STING pathway in tumors and have minimal effect on myeloid cells in the periphery. This evidence concerns the gene STING1 and neoplasm.